Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients

Evolocumab, which can lower low-density lipoprotein (LDL) cholesterol levels by approximately 60% and prevent cardiovascular events in patients with cardiovascular disease, is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Some studies have investigated it...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chin-Chou, Charng, Min-Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800550/
https://www.ncbi.nlm.nih.gov/pubmed/31686828
http://dx.doi.org/10.2147/TCRM.S193971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800550/
https://www.ncbi.nlm.nih.gov/pubmed/31686828
http://dx.doi.org/10.2147/TCRM.S193971

Ejemplares similares